window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : November 16, 2025

  • News
  • About Us
Contact Us

Clinical Innovation

  • CDMOs & Manufacturing,Drug Development,Market Access & Commercialization,Partnerships & Funding,Supply Chain & Logistics,Technology and platforms,Women in Pharma

    CPHI Frankfurt’s puts spotlight on innovation, partnerships and sustainability – an interview with event director, Tara Dougal

    As CPHI Frankfurt 2025 prepares to welcome more than 60,000 [...]

    September 11, 2025
  • Precision medicine

    First participant dosed in ACT-EARLY: A landmark prevention study

    BridgeBio Pharma has announced that the first participant has been [...]

    May 13, 2025
  • Artificial Intelligence

    ICU level care not definitive indicator for sepsis, new study shows

    April 22, 2025
  • Clinical Trials

    CluePoints’ time similarity test shortlisted for Citeline award for clinical trial innovation

    April 24, 2025
  • Artificial Intelligence

    New research from eClinical Solutions highlights AI adoption and focus on risk-based strategies in 2025

    June 5, 2025

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2025 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Clairity raises $43 million to launch FDA-authorized AI platform for breast cancer risk prediction
    Categories: Artificial Intelligence, Biotech, Clinical Development, Diagnostics, Digital Health, Drug Development, Global health, Healthcare leadership, Precision medicine, Women's Health
  • FDA approves Kura and Kyowa Kirin’s ziftomenib for relapsed or refractory AML
    Categories: Drug approval, Oncology, Pharmaceuticals and therapeutics
  • Successful treatment for ALS could deliver billions in global value
    Categories: Neurosciences, Rare Diseases, Research & Development
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top